MRA (Tocilizumab) ( DrugBank: Tocilizumab )
2 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 46 | 悪性関節リウマチ | 4 |
| 107 | 若年性特発性関節炎 | 1 |
46. 悪性関節リウマチ
臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00144534 (ClinicalTrials.gov) | June 2004 | 2/9/2005 | Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA213JP | An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With RA Who Participated in Study MRA213JP | Rheumatoid Arthritis | Drug: MRA (Tocilizumab) | Chugai Pharmaceutical | NULL | Completed | 20 Years | 75 Years | Both | 115 | Phase 3 | NULL |
| 2 | NCT00144508 (ClinicalTrials.gov) | March 2003 | 2/9/2005 | Phase III Comparative Study(Open-Label) of MRA for Rheumatoid Arthritis(RA) | An Open-Label, Phase III Study to Evaluate the Efficacy and Safety of MRA in Patients With RA | Rheumatoid Arthritis | Drug: MRA (Tocilizumab);Other: current treatment | Chugai Pharmaceutical | NULL | Completed | 20 Years | N/A | Both | 306 | Phase 3 | NULL |
| 3 | JPRN-JapicCTI-050016 | 02/09/2005 | A controlled, randomized trial of MRA monotherapy in patients with rheumatoid arthritis(RA) | A controlled, randomized trial of MRA monotherapy in patients with rheumatoid arthritis(RA) | RA | Intervention name : MRA (tocilizumab) Dosage And administration of the intervention : Intravenous infusion | Chugai Pharmaceutical Co., Ltd. | NULL | 20 | Phase 3 | NULL | |||||
| 4 | JPRN-JapicCTI-050018 | 02/09/2005 | Double-blind, parallel-group, controlled Phase 3 study of MRA in rheumatoid arthritis(RA) | Double-blind, parallel-group, controlled Phase 3 study of MRA in rheumatoid arthritis(RA) | RA | Intervention name : MRA (tocilizumab) Dosage And administration of the intervention : Intravenous infusion | Chugai Pharmaceutical Co., Ltd. | NULL | 20 | 74 | Phase 3 | NULL |
107. 若年性特発性関節炎
臨床試験数 : 447 / 薬物数 : 297 - (DrugBank : 57) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 146
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-JapicCTI-050017 | 02/09/2005 | Phase 3 clinical study of MRA in patients with systemic juvenile idiopathic arthritis (sJIA) | Phase 3 clinical study of MRA in patients with systemic juvenile idiopathic arthritis (sJIA) | sJIA | Intervention name : MRA (tocilizumab) Dosage And administration of the intervention : Intravenous infusion | Chugai Pharmaceutical Co., Ltd. | NULL | 2 | 19 | Phase 3 | NULL |